CYP1A1, GSTM1, GSTT1 and TP53 Polymorphisms and Risk of Gallbladder Cancer in Bolivians

• Published in: Asian Pacific journal of cancer prevention : APJCP Vol. 17; no. 2; p. 781
• Main Authors: Sakai, Kazuaki, Loza, Ernesto, Roig, Guido Villa-Gomez, Nozaki, Ryoko, Asai, Takao, Ikoma, Toshikazu, Tsuchiya, Yasuo, Kiyohara, Chikako, Yamamoto, Masaharu, Nakamura, Kazutoshi
• Format: Journal Article
• Language: English
• Published: Thailand 2016
• Subjects: Adult; Biomarkers, Tumor - genetics; Bolivia; Case-Control Studies; Cytochrome P-450 CYP1A1 - genetics; Female; Follow-Up Studies; Gallbladder - metabolism; Gallbladder - pathology; Gallbladder Neoplasms - etiology; Gallbladder Neoplasms - pathology; Genetic Predisposition to Disease; Genotype; Glutathione Transferase - genetics; Humans; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Polymorphism, Genetic - genetics; Polymorphism, Restriction Fragment Length; Prognosis; Risk Factors; Tumor Suppressor Protein p53 - genetics
• ISSN: 2476-762X

The Plurinational State of Bolivia (Bolivia) has a high incidence rate of gallbladder cancer (GBC). However, the genetic and environmental risk factors for GBC development are not well understood. We aimed to assess whether or not cytochrome P450 (CYP1A1), glutathione S-transferase mu 1 (GSTM1), theta 1 (GSTT1) and tumor suppressor protein p53 (TP53) genetic polymorphisms modulate GBC susceptibility in Bolivians. This case-control study covered 32 patients with GBC and 86 healthy subjects. GBC was diagnosed on the basis of histological analysis of tissues at the Instituto de Gastroenterologia Boliviano-Japones (IGBJ); the healthy subjects were members of the staff at the IGBJ. Distributions of the CYP1A1 rs1048943 and TP53 rs1042522 polymorphisms were assayed using PCR-restriction fragment length polymorphism assay. GSTM1 and GSTT1 deletion polymorphisms were detected by a multiplex PCR assay. The frequency of the GSTM1 null genotype was significantly higher in GBC patients than in the healthy subjects (odds ratio [OR], 2.35; 95% confidence interval [CI], 1.03-5.37; age-adjusted OR, 3.53; 95% CI, 1.29-9.66; age- and sex-adjusted OR, 3.40; 95% CI, 1.24-9.34). No significant differences were observed in the frequencies of CYP1A1, GSTT1, or TP53 polymorphisms between the two groups. The GSTM1 null genotype was associated with increased GBC risk in Bolivians. Additional studies with larger control and case populations are warranted to confirm the association between the GSTM1 deletion polymorphism and GBC risk suggested in the present study.